Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Current Deferred Revenue of $33.1 million for Q1 2026, up 1.49% year-over-year from $32.6 million in Q1 2025, and down 70.31% quarter-over-quarter from $111.3 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $33.1 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 1.49% year-over-year to $33.1 million; the TTM figure through Mar 2026 stood at $33.1 million (up 1.49% YoY), while the FY2025 annual figure was $111.3 million, up 589.49% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $33.1 million, down from $111.3 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $111.9 million in Q3 2025, with the low at $16.1 million in Q4 2024.
- The 4-year median for Current Deferred Revenue is $26.5 million (2024), against an average of $41.4 million.
- Peak annual rise in Current Deferred Revenue reached 589.49% in 2025, while the deepest fall reached 45.2% in 2025.
- Monte Rosa Therapeutics' Current Deferred Revenue stood at $17.7 million in 2023, then fell by 8.66% to $16.1 million in 2024, then jumped by 589.49% to $111.3 million in 2025, then sank by 70.31% to $33.1 million in 2026.
- Business Quant data shows GLUE's Current Deferred Revenue at $33.1 million in Q1 2026, $111.3 million in Q4 2025, and $111.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 105.62 Mn |
| Mar 31, 2026 | 33.06 Mn |
| Dec 31, 2025 | 111.33 Mn |
| Sep 30, 2025 | 111.89 Mn |
| Jun 30, 2025 | 18.41 Mn |
| Mar 31, 2025 | 32.58 Mn |
| Dec 31, 2024 | 16.15 Mn |
| Sep 30, 2024 | 18.92 Mn |
| Jun 30, 2024 | 33.60 Mn |
| Mar 31, 2024 | 20.41 Mn |
| Dec 31, 2023 | 17.68 Mn |